Selection of a novel drug-response predictor in esophageal cancer: A novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response

International Journal of Oncology

Volumn 32, Issue 2, 2008, Pages 413-423

  Fumoto, Shoichi ^a   Shimokuni, Tatsushi ^a   Tanimoto, Keiji ^a   Hiyama, Keiko ^a   Otani, Keiko ^a   Ohtaki, Megu ^a   Hihara, Jun ^a   Yoshida, Kazuhiro ^b   Hiyama, Eiso ^a   Noguchi, Tsuyoshi ^c   Nishiyama, Masahiko ^a,d  

^a HIROSHIMA UNIVERSITY   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c OITA UNIVERSITY   (Japan)

^d SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

Drug sensitivity; Esophageal cancer; Gene expression; IFITMI; Microarray; Personalized medicine

Indexed keywords

CISPLATIN; FLUOROURACIL; INTERFERON INDUCED TRANSMEMBRANE PROTEIN 1; MEMBRANE PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WNT PROTEIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE FREE SURVIVAL; DNA MICROARRAY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; LOW DRUG DOSE; MARKER GENE; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

EID: 38849138987     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.2.413     Document Type: Article

References (40)

1. Evans WE and Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487-491, 1999.
2. Watters JW and McLeod HL: Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta 1603: 99-111, 2003.
3. Robert J: Pharmacogenetics and pharmacogenomics as new tools to optimise cancer chemotherapy. J Chemother 16 (Suppl 4): 22-24, 2004.
4. Sadée W and Dai Z: Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 14 (Review Issue 2): R207-R214, 2005.
5. Marsh S: Impact of pharmacogenomics on clinical practice in oncology. Mol Diagn Ther 11: 79-82, 2007.
6. Sun Z and Yang P: Gene expression profiling on lung cancer outcome prediction: present clinical value and future premise. Cancer Epidemiol Biomarkers Prev 15: 2063-2068, 2006.
7. Mariette C, Piessen G and Triboulet JP: Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 8: 545-553, 2007.
8. Martin MG, Govindan R and Morgensztern D: Second-line therapy for esophageal cancer. Expert Rev Anticancer Ther 7: 871-876, 2007.
9. McLeod HL and Evans WE: Pharmacogenomics: unlocking the human genome for better dmg therapy. Annu Rev Pharmacol Toxicol 41: 101-121, 2001.
10. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, Mesirov JP, Lander ES and Golub TR: Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 98: 10787-10792, 2001.
11. Tanaka T, Tanimoto K, Otani K, Satoh K, Ohtaki M, Yoshida K, Toge T, Yahata H, Tanaka S, Chayama K, Okazaki Y, Hayashizaki Y, Hiyama K and Nishiyama M: Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer 111: 617-626, 2004.
12. Shimokuni T, Tanimoto K, Hiyama K, Otani K, Ohtaki M, Hihara J, Yoshida K, Noguchi T, Kawahara K, Natsugoe S, Aikou T, Okazaki Y, Hayashizaki Y, Sato Y, Todo S, Hiyama E and Nishiyama M: Chemosensitivity prediction in esophageal squamous cell carcinoma: novel marker genes and efficacyprediction formulae using their expression data. Int J Oncol 28: 1153-1162, 2006.
13. Komatsu M, Hiyama K, Tanimoto K, Yunokawa M, Otani K, Ohtaki M, Hiyama E, Kigawa J, Ohwada M, Suzuki M, Nagai N, Kudo Y and Nishiyama M: Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol Cancer Ther 5: 767-775, 2006.
14. Ohtaki M, Otani K, Satoh K, Kawamura T, Hiyama K and Nishiyama M: Model-based analysis of microarray data: Exploration of differentially expressed genes between two cell types based on a two-dimensional mixed normal model. Jpn J Biometrics 26: 31-48, 2005.
15. Hiyama K, Otani K, Ohtaki M, Satoh K, Kumazaki T, Takahashi T, Mitsui Y, Okazaki Y, Hayashizaki Y, Omatsu H, Noguchi T, Tanimoto K and Nishiyama M: Differentially expressed genes throughout the cellular immortalization processes are quite different between normal human fibroblasts and endothelial cells. Int J Oncol 27: 87-95, 2005.
16. Rousseeuw PJ: Least median of squares regression. J Am Statist Assoc 79: 871-880, 1984.
17. Dupuy A and Simon RM: Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99: 147-157, 2007.
18. Andreu P, Colnot S, Godard C, Lanrent-Puig P, Lamarque D, Kahn A, Perret C and Romagnolo B: Identification of the IFITM family as a new molecular marker in human colorectal tumors. Cancer Res 66: 1949-1955, 2006.
19. Yang G, Xu Y, Chen X and Hu G: IFITM1 plays an essential role in the antiproliferative action of interferon-γ. Oncogene 26: 594-603, 2007.
20. Lickert H, Cox B, Wehrle C, Taketo MM, Kemler R and Rossant J: Dissecting Wnt/β-catenin signaling during gastrulation using RNA interference in mouse embryos. Development 132: 2599-2609, 2005.
21. Tsai MH, Cook JA, Chandramouli GV, DeGraff W, Yan H, Zhao S, Coleman CN, Mitchell JB and Chuang EY: Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res 67: 3845-3852, 2007.
22. Akyerli CB, Beksac M, Holko M, Frevel M, Dalva K, Ozbek U, Soydan E, Ozcan M, Ozet G, Ilhan O, Gurman G, Akan H, Williams BR and Ozcelik T: Expression of IFITM1 in chronic myeloid leukemia patients. Leuk Res 29: 283-286, 2005.
23. Bani MR, Nicoletti MI, Alkharouf NW, Ghilardi C, Petersen D, Erba E, Sausville EA, Liu ET and Giavazzi R: Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther 3: 111-121, 2004.
24. Leung KC, Brce J, Doyle N, Lee HJ, Leong GM, Sjögren K and Ho KK: Regulation of growth hormone signaling by selective estrogen receptor modulators occurs through suppression of protein tyrosine phosphatases. Endocrinology 148: 2417-2423, 2007.
25. + anaplastic large-cell lymphoma. Blood 108: 2796-2803, 2006.
26. Das S, Cho J, Lambertz I, Kelliher MA, Eliopoulos AG, Du K and Tsichlis PN: Tpl2/cot signals activate ERK, JNK, and NF-κB in a cell-type and stimulus-specific manner. J Biol Chem 280: 23748-23757, 2005.
27. Aparecida Alves C, Silva ID, Villanova FE, Nicolau SM, Custódio MA, Bortoletto C and Goncalves WJ: Differential gene expression profile reveals overexpression of MAP3K8 in invasive endometrioid carcinoma. Eur J Gynaecol Oncol 27: 589-593, 2006.
28. Clark AM, Reynolds SH, Anderson M and Wiest JS: Mutational activation of the MAP3K8 protooncogene in lung cancer. Genes Chromosomes Cancer 41: 99-108, 2004.
29. Kurehara H, Ishiguro H, Kimura M, Mitsui A, Ando T, Sugito N, Mori R, Takashima N, Ogawa R, Fujii Y and Kuwabara Y: A novel gene, RSRC2, inhibits cell proliferation and affects survival in esophageal cancer patients. Int J Oncol 30: 421-428, 2007.
30. McDonough WS, Tran NL and Berens ME: Regulation of glioma cell migration by serine-phosphorylated P311. Neoplasia 7: 862-872, 2005.
31. Mariani L, McDonough WS, Hoelzinger DB, Beaudry C, Kaczmarek E, Coons SW, Giese A, Moghaddam M, Seiler RW and Berens ME: Identification and validation of P311 as a glioblastoma invasion gene using laser capture microdissection. Cancer Res 61: 4190-4196, 2001.
32. King LM and Francomano CA: Characterization of a human gene encoding nucleosomal binding protein NSBP1. Genomics 71: 163-173, 2001.
33. Dumon-Jones V, Frappart PO, Tong WM, Sajithlal G, Hulla W, Schmid G, Herceg Z, Digweed M and Wang ZQ: Nbn heterozygosity renders mice susceptible to tumor formation and ionizing radiation-induced tumorigenesis. Cancer Res 63: 7263-7269, 2003.
34. Jensen KB and Watt FM: Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence. Proc Natl Acad Sci USA 103: 11958-11963, 2006.
35. Ljuslinder I, Malmer B, Golovleva I, Thomasson M, Grankvist K, Höckenstrom T, Emdin S, Jonsson Y, Hedman H and Henriksson R: Increased copy number at 3p14 in breast cancer. Breast Cancer Res 7: R719-R727, 2005.
36. Tanemura A, Nagasawa T, Inui S and Itami S: LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg 31: 423-430, 2005.
37. Welting TJ, Peters FM, Hensen SM, van Doom NL, Kikkert BJ, Raats JM, van Venrooij WJ and Pruijn GJ: Heterodimerization regulates RNase MRP/RNase P association, localization, and expression of Rpp20 and Rpp25. RNA 13: 65-75, 2007.
38. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K and Masaki T: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86: 2863-2867, 1989.
39. Jiao WJ, Xu J, Pan H, Wang TY and Shen Y: Effect of endothelin-1 in esophageal squamous cell carcinoma invasion and its correlation with cathepsin B. World J Gastroenterol 13: 402-4005, 2007.
40. Wilson JL, Burchell J and Grimshaw MJ: Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1. Cancer Res 66: 11802-11807, 2006.